Pyxis Oncology, Inc. - 8-K Filing
Pyxis Oncology announced updated Phase 1 monotherapy trial data for micvotabart pelidotin in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma, showing a confirmed objective response rate of 36%. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $PYXS